thiazoles has been researched along with bromocriptine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (43.48) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffmann, WE; Hyslop, DK; Piercey, MF; Smith, MW | 1 |
| Fici, GJ; Sethy, VH; VonVoigtlander, PF; Wu, H | 1 |
| Hall, ED; Oostveen, JA; Sethy, VH; Wu, H | 1 |
| Kitamura, Y; Kohno, Y; Nakazawa, M; Nomura, Y | 1 |
| Wienkers, LC; Wynalda, MA | 1 |
| Guttman, M | 1 |
| Kakimura, JI; Kitamura, Y; Kohno, Y; Kosaka, T; Matsuoka, Y; Nomura, Y; Taniguchi, T | 1 |
| Factor, SA | 1 |
| Weiner, WJ | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Clarke C, E; Clarke J, A; Speller J, M | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Jankovic, J; Le, WD | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Gekht, AB | 1 |
| Blackman, JA; Buck, ML; Conaway, MR; Patrick, PD | 1 |
| Bankowski, BJ; Zacur, HA | 1 |
| Hasegawa, K; Kowa, H; Kuno, S; Mizuno, Y; Origasa, H; Yamamoto, M; Yanagisawa, N | 1 |
| Lang, AE; Razmy, A; Shapiro, CM | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Chassain, C; Durif, F; Hafidi, A; Ouachikh, O; Pagès, G | 1 |
8 review(s) available for thiazoles and bromocriptine
| Article | Year |
|---|---|
Dopamine agonists.
Topics: Apomorphine; Benzothiazoles; Bromocriptine; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Receptors, Dopamine; Thiazoles; Treatment Outcome | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Bromocriptine; Cell Culture Techniques; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Models, Animal; Neuroprotective Agents; Parkinson Disease; Pergolide; Pramipexole; Substantia Nigra; Thiazoles | 2001 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
2 trial(s) available for thiazoles and bromocriptine
| Article | Year |
|---|---|
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Pramipexole; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome | 1997 |
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Demography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Quality of Life; Thiazoles; Time Factors; Treatment Outcome | 2003 |
13 other study(ies) available for thiazoles and bromocriptine
| Article | Year |
|---|---|
Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Bromocriptine; CHO Cells; Cricetinae; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Substantia Nigra; Thiazoles | 1996 |
D1 dopamine receptor activity of anti-parkinsonian drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Benzothiazoles; Bromocriptine; Cells, Cultured; Cerebellum; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiazoles | 1997 |
Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.
Topics: Adenosine Triphosphate; Animals; Benzothiazoles; Body Temperature; Bromocriptine; Cerebellum; Cyclic GMP; Dopamine Agonists; Male; Motor Activity; Neurons; Neuroprotective Agents; Neurotoxins; Olivary Nucleus; Pramipexole; Pyridines; Rats; Rats, Wistar; Thiazoles | 1997 |
Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Azepines; Benzothiazoles; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Homovanillic Acid; In Vitro Techniques; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neostriatum; Pramipexole; Synaptosomes; Thiazoles | 1997 |
Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.
Topics: Benzothiazoles; Bromocriptine; Cytochrome P-450 Enzyme Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Pergolide; Pramipexole; Thiazoles | 1997 |
Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Antiparkinson Agents; Apoptosis; Azepines; Benzothiazoles; Bromocriptine; Bucladesine; Caspase 3; Caspases; Dopamine Agonists; Humans; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
The use of dopamine enhancing medications with children in low response states following brain injury.
Topics: Adolescent; Adult; Amantadine; Arousal; Awareness; Benzothiazoles; Brain Injuries; Bromocriptine; Child; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Methylphenidate; Neuropsychological Tests; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome; Unconsciousness | 2003 |
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Topics: Aged; Benzothiazoles; Bromocriptine; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Ergot Alkaloids; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Polysomnography; Pramipexole; Prospective Studies; Sleep; Thiazoles; Wakefulness | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
mGlu5 receptor antagonist blocks bromocriptine-induced conditioned place preference in bilateral mesolimbic-lesioned rat.
Topics: Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Bromocriptine; Conditioning, Operant; Desipramine; Excitatory Amino Acid Antagonists; Exploratory Behavior; Gene Expression Regulation; Male; Maze Learning; Nucleus Accumbens; Oxidopamine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Reinforcement, Psychology; Thiazoles; Ventral Tegmental Area | 2017 |